PIP

Sir Speedy, PIP and Signal Graphics Outpaced the Industry in 2023

Retrieved on: 
Friday, March 1, 2024

MISSION VIEJO, Calif., Feb. 29, 2024 /PRNewswire-PRWeb/ -- Franchise Services, Inc. reported an outstanding year for its brands Sir Speedy, PIP and Signal Graphics—nationally known franchise companies in the printing, signage and marketing services sector. Combined comparative sales growth for the company's print franchises increased 5% year-over-year in 2023, in contrast to the U.S. printing industry being down 3%.

Key Points: 
  • Franchise Services, Inc. reported an outstanding year for its brands Sir Speedy, PIP and Signal Graphics—nationally known franchise companies in the printing, signage and marketing services sector.
  • MISSION VIEJO, Calif., Feb. 29, 2024 /PRNewswire-PRWeb/ -- Franchise Services, Inc. reported an outstanding year for its brands Sir Speedy, PIP and Signal Graphics—nationally known franchise companies in the printing, signage and marketing services sector.
  • Combined comparative sales growth for the company's print franchises increased 5% year-over-year in 2023, in contrast to the U.S. printing industry being down 3%.
  • The growth is also a reflection of several new, and very motivated owners, who have joined the Sir Speedy and PIP networks.

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

Retrieved on: 
Wednesday, January 31, 2024

CEL-SCI Corporation (NYSE American: CVM) today announced that the European Medicines Agency (EMA) Paediatric Committee granted CEL-SCI a product-specific waiver of strict requirements for commercialization of cancer drugs in the European Union (EU).

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) today announced that the European Medicines Agency (EMA) Paediatric Committee granted CEL-SCI a product-specific waiver of strict requirements for commercialization of cancer drugs in the European Union (EU).
  • According to the opinion letter:
    This press release features multimedia.
  • Its objective is to bolster investigation and development of medicinal products for the paediatric population.
  • Much has been said publicly about these “onerous” requirements and how difficult they can be to navigate.3
    3 Sharma, V. “‘Not What We Expected,’ R&D Industry Says Of ‘Onerous’ EU Paediatric Regulation”.

ViewSonic Debuts 245-inch Customizable All-in-One LED Displays at ISE 2024

Retrieved on: 
Monday, January 29, 2024

BREA, Calif. , Jan. 29, 2024 /PRNewswire/ -- ViewSonic Corp., a leading global provider of visual solutions, is showcasing its new LDC series, a customizable addition to its advanced All-in-One LED display lineup at Integrated Systems Europe (ISE) 2024 — marking a significant breakthrough in the LED display technology's product design and expansion of the company's offering. ViewSonic's new customizable All-in-One LED displays merge the advantages of traditional and All-in-One LED displays, facilitating the effortless creation of large, vibrant visuals suitable for business, commercial, and public environments.

Key Points: 
  • ViewSonic's new customizable All-in-One LED displays merge the advantages of traditional and All-in-One LED displays, facilitating the effortless creation of large, vibrant visuals suitable for business, commercial, and public environments.
  • At ViewSonic, we are leveraging our expertise in visual display innovation to enhance the versatility of our All-in-One LED display lineup.
  • On the other hand, All-in-One LED displays address the installation complexities while offering an integrated design but come in fixed sizes.
  • Visitors at ISE 2024 will experience the innovative All-in-One LED displays presented by ViewSonic.

ViewSonic Debuts 245-inch Customizable All-in-One LED Displays at ISE 2024

Retrieved on: 
Monday, January 29, 2024

BREA, Calif., Jan. 29, 2024 /PRNewswire/ -- ViewSonic Corp., a leading global provider of visual solutions, is showcasing its new LDC series, a customizable addition to its advanced All-in-One LED display lineup at Integrated Systems Europe (ISE) 2024 — marking a significant breakthrough in the LED display technology's product design and expansion of the company's offering. ViewSonic's new customizable All-in-One LED displays merge the advantages of traditional and All-in-One LED displays, facilitating the effortless creation of large, vibrant visuals suitable for business, commercial, and public environments.

Key Points: 
  • ViewSonic's new customizable All-in-One LED displays merge the advantages of traditional and All-in-One LED displays, facilitating the effortless creation of large, vibrant visuals suitable for business, commercial, and public environments.
  • At ViewSonic, we are leveraging our expertise in visual display innovation to enhance the versatility of our All-in-One LED display lineup.
  • On the other hand, All-in-One LED displays address the installation complexities while offering an integrated design but come in fixed sizes.
  • Visitors at ISE 2024 will experience the innovative All-in-One LED displays presented by ViewSonic.

Endo Announces Publication of New XIAFLEX® (collagenase clostridium histolyticum) Survey Data in Journal of Hand Surgery Global Open

Retrieved on: 
Wednesday, January 24, 2024

DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1

Key Points: 
  • DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1
    Consensus-based study findings among expert hand surgeons indicate that XIAFLEX® (collagenase clostridium histolyticum) has a wide-ranging application for the appropriate treatment of Dupuytren's contracture in patients with varying degrees of disease severity and functional impairment.
  • Results from the published research indicate a high level of consensus for using XIAFLEX for the treatment of one- or two-finger metacarpophalangeal (MP) joint contractures, most one- or two-finger proximal interphalangeal (PIP) joint contractures, and most combined MP and PIP joint contractures.
  • "Healthcare providers and patients can choose among multiple surgical and nonsurgical treatment options for Dupuytren's disease, and without established guidelines, the process for sorting through those choices can be overwhelming," said Dr. Gary M. Pess, a hand and upper extremity surgeon and lead author of the study.
  • "This study provides insight from experienced hand surgeons about using XIAFLEX to treat varying degrees of Dupuytren's contracture."

Endo Announces Publication of New XIAFLEX® (collagenase clostridium histolyticum) Survey Data in Journal of Hand Surgery Global Open

Retrieved on: 
Wednesday, January 24, 2024

DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1

Key Points: 
  • DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1
    Consensus-based study findings among expert hand surgeons indicate that XIAFLEX® (collagenase clostridium histolyticum) has a wide-ranging application for the appropriate treatment of Dupuytren's contracture in patients with varying degrees of disease severity and functional impairment.
  • Results from the published research indicate a high level of consensus for using XIAFLEX for the treatment of one- or two-finger metacarpophalangeal (MP) joint contractures, most one- or two-finger proximal interphalangeal (PIP) joint contractures, and most combined MP and PIP joint contractures.
  • "Healthcare providers and patients can choose among multiple surgical and nonsurgical treatment options for Dupuytren's disease, and without established guidelines, the process for sorting through those choices can be overwhelming," said Dr. Gary M. Pess, a hand and upper extremity surgeon and lead author of the study.
  • "This study provides insight from experienced hand surgeons about using XIAFLEX to treat varying degrees of Dupuytren's contracture."

Endo Announces New Data for Dupuytren's Contracture Presented at the American Association for Hand Surgery Annual Meeting

Retrieved on: 
Friday, January 19, 2024

DUBLIN, Jan. 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting.

Key Points: 
  • DUBLIN, Jan. 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting.
  • Endo provided funding through an investigator-initiated research grant.
  • "This medical knowledge presented at the AAHS annual meeting may help healthcare providers treat patients with Dupuytren's contracture and, hopefully, improve patient outcomes," said Dr. Jason Nydick, an orthopedic hand surgeon at Florida Orthopaedic Institute in Tampa, Florida and lead investigator of the studies.
  • "The results related to the effective treatment of the proximal interphalangeal (PIP) joint with XIAFLEX are particularly noteworthy."

Endo Announces New Data for Dupuytren's Contracture Presented at the American Association for Hand Surgery Annual Meeting

Retrieved on: 
Friday, January 19, 2024

DUBLIN, Jan. 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting.

Key Points: 
  • DUBLIN, Jan. 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting.
  • Endo provided funding through an investigator-initiated research grant.
  • "This medical knowledge presented at the AAHS annual meeting may help healthcare providers treat patients with Dupuytren's contracture and, hopefully, improve patient outcomes," said Dr. Jason Nydick, an orthopedic hand surgeon at Florida Orthopaedic Institute in Tampa, Florida and lead investigator of the studies.
  • "The results related to the effective treatment of the proximal interphalangeal (PIP) joint with XIAFLEX are particularly noteworthy."

Premier Ice Prospects Joins Forces with 200x85 to Elevate Girls Youth Hockey Experiences

Retrieved on: 
Wednesday, January 3, 2024

CHICAGO, Jan. 3, 2024 /PRNewswire/ -- Premier Ice Prospects (PIP Hockey) and 200x85 are excited to announce a strategic merger aimed at maximizing experiences and developmental opportunities for girls youth hockey players. The partnership between PIP Hockey and 200x85 brings together the expertise and resources of two prominent organizations dedicated to advancing the growth of girls hockey at both the grassroots and elite levels.

Key Points: 
  • CHICAGO, Jan. 3, 2024 /PRNewswire/ -- Premier Ice Prospects (PIP Hockey) and 200x85 are excited to announce a strategic merger aimed at maximizing experiences and developmental opportunities for girls youth hockey players.
  • Kevin Mann , President & CEO of 200x85 , expressed his enthusiasm, stating, "We are thrilled to welcome Premier Ice Prospects into the 200x85 hockey family.
  • "Collaboratively, Premier Ice Prospects and 200x85 are dedicated to taking the girls hockey experience to the next level.
  • The partnership between Premier Ice Prospects, 200x85, and CCM Hockey underscores the like-minded dedication to fostering the continued growth of girls youth hockey.

Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients

Retrieved on: 
Wednesday, December 20, 2023

Study recruited more than 100 adolescents, with primary aim to evaluate safety profile

Key Points: 
  • Study recruited more than 100 adolescents, with primary aim to evaluate safety profile
    Liege, Belgium, 20 December 2023 – 17:45 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the completion of a pediatric study of its marketed contraceptive ESTELLE® in adolescent women.
  • The primary endpoint of the study, which is being conducted in Estonia, Finland, Georgia, Latvia, Poland and Sweden, is to evaluate the safety of ESTELLE® in post-menarchal subjects.
  • Graham Dixon, Chief Scientific Officer of Mithra, commented, “The completion of this pediatric study on schedule is another important milestone for Mithra.
  • Mithra is undertaking this study under a Pediatric Investigation Plan (PIP) agreed with the European Medicines Agency (EMA).